| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
(From the Radiation Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland)
Murine leukemia L1210 has been treated with cyclophosphamide and 4 sublines have been developed from the tumor cells surviving drug therapy. Biologic studies have demonstrated a marked alteration of virulence compared to the parent tumor and striking cytogenetic modifications have been found to exist. Serial examinations over an interval of 22 weekly transplant generations have demonstrated a biologic and cytogenetic instability characterized by, generally, a tendency for return toward control values.
Received 11/19/64.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |